Tagged: BIO

Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses

GREENWICH, Connecticut, Aug. 22, 2014 /PRNewswire/ — Aptuit LLC announces that Aptuit SSCI, located in West Lafayette, Indiana, has enhanced its capabilities in the areas of structure determination and characterization of small and large molecules, including biologic drugs, metabolites, and polymers, through the addition of the Bruker maXisPlus Q-TOF mass spectrometer.

In making the announcement, Dr. Jonathan Goldman, CEO, Aptuit, said, “The expanded large molecule capability enhances our early development support for the fastest growing sector of the pharmaceutical industry and provides our scientists with the ability to identify active and/or high percentage metabolites in drugs as outlined in the United States Food and Drug Administration Guidance on Metabolites in Safety Testing (MIST).”

Dr. Patrick Tishmack, Director of Analytical Development at Aptuit SSCI, explained that ultra high mass resolution is particularly important in conducting impurity assays of drug substances and drug products, with a limit of detection in the pg/mL to fg/mL range. He clarified the significance of the high sensitivity by saying, “Q-TOF mass spectrometry is a fast and accurate analytical method for characterizing low levels of analytes yet its range from 20 Da to 40,000 Da also enables the analyses of small molecules, polymers, carbohydrates, oligonucleotides, and proteins such as antibodies.”

According to Dr. Tishmack, this addition brings significant value to Aptuit’s clients. “When high resolution mass spectrometry capability is coupled with Aptuit SSCI’s industry-leading expertise in solid state chemistry, the resulting data and corresponding expert scientific interpretation will be at a standard that is unmatched in the contract preclinical research industry.”

The Q-TOF MS, which will be installed and operational by October 2014, will allow unambiguous assignment of molecular formulae for small molecules. In addition to faster sample analysis, generally easier method development is achieved through its implementation. The equipment’s higher throughput translates into a more rapid turnaround for a large number of samples.

For more information, please send an email to info@ssci-inc.com or contact Aptuit SSCI at + 1 800 375 2179.

Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Pharmaceutical Sciences and Aptuit INDiGO® (a fixed-cost program that accelerates drug development). Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 700 employees in Europe and the United States. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com.

China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results

Earnings Call Scheduled for 8:00 a.m. ET on August 29, 2014

HONG KONG, Aug. 21, 2014 /PRNewswire/ — China Cord Blood Corporation (NYSE: CO) (the “Company”) today announced its plan to release financial results for the first quarter of fiscal year 2015 on Thursday, August 28, 2014, after market close in the US. 

The Company will host a conference call at 8:00 a.m. ET on Friday, August 29, 2014 to discuss its financial performance and give a brief overview of the Company’s recent developments, followed by a question and answer session.  Interested parties may access the audio webcast through the Company’s IR website at http://ir.chinacordbloodcorp.com.  A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL link above.  Listeners may also access the call by dialing 1-631-514-2526 or 1-855-298-3404 for US callers or +852-5808-3202 for Hong Kong callers, access code: 1856118. 

Please dial in ten minutes prior to the conference call to ensure proper connection, and be prepared to provide your name and company name to the operator.

Supplemental financial information referenced in the conference call and the first quarter of fiscal 2015 earnings press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:00 p.m. ET on Thursday, August 28, 2014 and in the Company’s Report on Form 6-K for the month of August 2014 available on the Securities and Exchange Commission’s website at www.sec.gov.  

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses.  Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today.  China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services.  For more information, please visit the Company’s website at http://www.chinacordbloodcorp.com.  

For more information, please contact:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com   

ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: william.zima@icrinc.com

Biocompatible Protective Coatings Widen Application Scope in Medical Devices, Finds Frost & Sullivan

— Blended products that include therapeutic coatings of different materials are making waves in the industry

MOUNTAIN VIEW, Calif., Aug. 12, 2014 /PRNewswire/ — Innovations will surge in the protective coatings industry by 2020, giving rise to a range of improved biocompatible and durable coatings that enable implant devices for use in orthopedic, orthodontic and cardiac applications. The International Organization for Standardization (ISO) and American Society for Testing and Materials (ASTM) are creating new standards for upcoming industry trends in protective coatings, further encouraging patent developments.

Logo – http://photos.prnewswire.com/prnh/20140808/134852

New analysis from Frost & Sullivan, Innovations in Protective Coatings for Medical Devices, finds that increasing biocompatibility is a major driver for implant coatings. Successful implant coatings enhance biocompatibility and promote healing processes by minimizing tissue rejection and better anchoring implants to the targeted area.

For complimentary access to more information on this research, please visit: http://bit.ly/1sl6idw.

Passivation – accomplished by coating implant material with polymer layers – is an upcoming area of research in coatings for biomedical applications. Passivation techniques have been successfully used in development of coatings and biomaterials to manufacture the most biocompatible implants.

“This is particularly important in cases of load-bearing implants with need for mechanical strength,” said Technical Insights Research Analyst Sanchari Chatterjee. “Developing specialized coatings and techniques that prevent aggressive cell growth and aid the production of desirable endothelial cells rather than smooth muscle cells will also be crucial.”

However, protective coatings require sophisticated raw materials that incur high costs. For instance, low availability of titanium, coupled with demand from industries such as aerospace, industrial and recreation make it an expensive resource.

Developing novel coating materials has been a trend in the industry for the last two years.  For example, use of spider silk, which is hypoallergenic, biodegradable and usable as coating for implants or as a drug carrier in pharmaceutics, is being researched as a coating for silicone implants.

In the meantime, combination products such as therapeutic coatings of different materials are creating a stir in the industry. Coatings that use solutions as surface treatments too are gaining momentum. For instance, bone implant surfaces enriched with biomolecules can accelerate the bone healing process.

“Research institutes have joined forces with industry players to evaluate a wide variety of biomolecules such as growth factors, bioactive proteins, enzymes and non-viral genes,” added Technical Insights Research Analyst Vivek Ninkileri. “As is evident, stakeholder initiatives, especially collaboration among research institutes, academia and medical device manufacturers will play a major role in the advancement of protective coating technologies.”

Innovations in Protective Coatings for Medical Devices, a part of the Technical Insights (http://www.technicalinsights.frost.com) subscription, analyses key innovations in protective coatings for medical devices to distinguish the chief developments and challenges in the market. Opportunity strategy evaluation, technology roadmap, impact analysis, and R&D development strategies are also discussed. Further, this study includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Innovations in Protective Coatings for Medical Devices
D556-TI

Contact:
Ariel Brown
Corporate Communications – North America
P: (210) 247.2481
F: (210) 348.1003
E: ariel.brown@frost.com

http://www.frost.com
http://www.technicalinsights.frost.com

Photo – http://photos.prnasia.com/prnh/20140811/8521404517LOGO

PW Medtech Group Limited Completes Acquisition of 100% Share Equity of Tianxinfu

Enters Biological Materials Segment and Creates New Profit Growth Drivers

Brings synergy through Outstanding Acquisition and Integration Capability

HONG KONG, Aug. 6, 2014 /PRNewswire/ — PW Medtech Group Limited (“PW Medtech” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 1358), a leading medical device company in China, announced the Group completed the acquisition of Beijing Tianxinfu Medical Appliance Co., Ltd. (“Tianxinfu”). Health Forward Holdings Limited and Beijing Fert Technology Co., Ltd., the wholly-owned subsidiaries of the Company acquired the entire equity interest in Tianxinfu with a total consideration of approximately RMB802.6 million. Tianxinfu has become an indirect wholly-owned subsidiary of the Group and contributed its revenue to it.

Tianxinfu is a high-tech enterprise integrating research, development, production and sales service. Its main products include regenerative medical biological materials and orthopedic implant products. As a leading company in the segment, Tianxinfu’s biological materials products are well recognized in China. Upon completion of the acquisition, Tianxinfu will become an indirect wholly-owned subsidiary of the Company and the Group will take over the market share of it in relation to biological materials products and will further expand the market share through synergy between the Company and Tianxinfu in research & development, production and distribution. Tianxinfu owns a total of 11 patents and has obtained 7 registration certificates for Class III medical devices. It has an extensive nationwide distribution network with over 150 distributors covering the major provinces in the PRC.

Mr. Jiang Liwei, Chief Executive Officer of PW Medtech said, “PW Medtech has long been focused on large, fast-growing and high margin segments of China’s medical device industry, with our leading market positions in the existing core business segments of orthopedic implants and advanced infusion sets, and with a strong research and development capability. Upon this strategic acquisition, the Group expanded the existing product portfolio by successfully entering into the biological materials segment, which has huge growth potential and high margin. It is expected to expand more medical applications of the biological materials products in other areas with R&D investments and technology advancement in the future. Meanwhile, the Group will continue to focus on organic growth derived from its core business segments and leverage on its outstanding acquisition and integration capability to boost its sustainable development.”